AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

TURK İLAÇ VE SERUM SANAYİ A.Ş.

Notice of Dividend Amount May 18, 2023

8900_rns_2023-05-18_8fa65a30-8cce-492b-9288-678ef982006d.html

Notice of Dividend Amount

Open in Viewer

Opens in native device viewer

Summary Info Kar Dağıtılmaması Hususunun Görüşüleceği Genel Kurul Toplantısı Tarihi eşleştirilmesi hakkında.
Update Notification Flag Yes
Correction Notification Flag No
Postponed Notification Flag No
Decision Date 18.05.2023
Date of Related General Assembly 23.06.2023
Type of Cash Dividend Payment Cash Dividend Will Not Be Paid
Currency Unit TRY
Stock Dividend Will Not Be Paid

Cash Dividend Payment Amount and Rates

Share Group Info Payment Cash Dividend To Be Paid For Share With Par Value of 1 TL - Gross (TL) Cash Dividend To Be Paid For Share With Par Value of 1 TL - Gross (%) Withholding Rate (%) Cash Dividend To Be Paid For Share With Par Value of 1 TL - Net (TL) Cash Dividend To Be Paid For Share With Par Value of 1 TL - Net (%)
A Grubu, İşlem Görmüyor, TRETRLC00014 0,0000000 0 0 0,0000000 0
B Grubu, TRILC, TRETRLC00022 0,0000000 0 0 0,0000000 0

Amount and Rate of Cash Dividend Stock Dividend Payment

Share Group Info Amount of Stock Dividend (TL) Rate of Stock Dividend (%)
A Grubu, İşlem Görmüyor, TRETRLC00014 0 0
B Grubu, TRILC, TRETRLC00022 0 0

Additional Explanations

Yönetim Kurulu'nun 18.05.2023 tarihli kararı ile;

Şirketimizin 2022 yılı faaliyetleri sonucu Sermaye Piyasası Mevzuatına göre oluşan 66.376.611-TL dönem kârından (Yasal Kayıtlara Göre 68.593.625,36-TL faaliyet karı vardır) üzerinden hesaplanan 3.429.681,26 TL tutarında Birinci Tertip Yedek Akçe düşüldükten sonra kalan Sermaye Piyasası Mevzuatına göre oluşan 62.946.929,7 TL'lik dönem kârından (Yasal Kayıtlara Göre - 65.163.944,10 TL faaliyet karı vardır) kısmın geçmiş yıllar karı hesabına kaydedilmesine ve bu nedenle kar payı dağıtılmamasına ve bu teklifin yapılacak olan Olağan Genel Kurul toplantısında ortakların onayına sunulmasına karar verilmiştir.

Saygılarımızla.

Supplementary Documents

Appendix: 1 Kardağıtım Tablosu.pdf

DIVIDEND DISTRIBUTION TABLE

TURK İLAÇ VE SERUM SANAYİ A.Ş. 01.01.2022/31.12.2022 Period Dividend Payment Table (TL)

1.Paid-In / Issued Capital 161.805.000
2. Total Legal Reserves (According to Legal Records) 3.429.681,27
Information on privileges in dividend distribution, if any, in the Articles of Association: YOKTUR
* Based on CMB Regulations Based on Legal Records
3. Current Period Profit 85.524.676 88.764.667,99
4. Taxes Payable (-) 19.148.065 20.171.042,63
5. Net Current Period Profit 66.376.611 68.593.625,36
6. Losses in Previous Years (-)
7. Primary Legal Reserve (-) 3.429.681,27 3.429.681,27
8. Net Distributable Current Period Profit 62.946.929,73 65.163.944,09
Dividend Advance Distributed (-)
Dividend Advance Less Net Distributable Current Period Profit
9. Donations Made During The Year ( + )
10. Donation-Added Net Distributable Current Period Profit on which First Dividend Is Calculated
11. First Dividend to Shareholders
* Cash
* Stock
12. Dividend Distributed to Owners of Privileged Shares
13. Other Dividend Distributed
* To the Employees
* To the Members of the Board of Directors
* To Non-Shareholders
14. Dividend to Owners of Redeemed Shares
15. Second Dividend to Shareholders 62.946.929,73 65.163.944,09
16. Secondary Legal Reserves 3.429.681,27 3.429.681,27
17. Statutory Reserves
18. Special Reserves
19. Extraordinary Reserves
20. Other Distributable Resources

Dividend Payment Rates Table

Share Group CASH DIVIDEND AMOUNT (TL) - NET STOCK DIVIDEND AMOUNT (TL) TOTAL DIVIDEND AMOUNT (TL) / NET DISTRIBUTABLE CURRENT PERIOD PROFIT (%) DIVIDEND TO BE PAID FOR SHARE WITH PAR VALUE OF 1 TL - NET (TL) DIVIDEND TO BE PAID FOR SHARE WITH PAR VALUE OF 1 TL - NET (%)
A Grubu 0 0 0 0 0
B Grubu 0 0 0 0 0
TOTAL 0 0 0 0 0

Talk to a Data Expert

Have a question? We'll get back to you promptly.